News

Hemophilia B Treatment, Idelvion, Approved for Use in Japan

Japan’s Ministry of Health, Labor and Welfare has approved CSL Behring‘s Idelvion (albutrepenonacog alfa) for the prevention of bleeding tendency in patients with hemophilia B. Hemophilia B, a bleeding condition that mainly affects males, is characterized by a deficient or defective factor IX protein, and is treated with intravenous infusion of factor IX.